Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer


28 Sep 2019


Poster Display session 1


Basic Science

Tumour Site

Breast Cancer


Miriam Nuncia-Cantarero


Annals of Oncology (2019) 30 (suppl_5): v1-v24. 10.1093/annonc/mdz238


M. Nuncia-Cantarero1, C. Nieto-Jiménez2, M. Burgos2, J.C. Montero3, A. Ocaña4, E.M. Galán-Moya1

Author affiliations

  • 1 Traslational Oncology Laboratory, University of Castilla-La Mancha, Regional Center for Biomedical Research (CRIB), 02008 - Albacete/ES
  • 2 Oncología Traslacional, Complejo Hospitalario Universitario de Albacete, 02006 - Albacete/ES
  • 3 Laboratorio 15, Centro de investigación del cáncer, 37007 - Salamanca/ES
  • 4 Drugs Development, Hospital Clínico San Carlos, 28040 - Madrid/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3577


Triple-negative breast cancer (TNBC) is the most aggressive among breast cancer subtypes, as these tumors frequently develop resistance to the treatment used. External signals provided by the surrounding tumor microenvironment (TM), which in mammary tumors is mainly constituted by adipose tissue (AT), control this resistance. Therefore, therapies that targets not only the cancer bulk but also its surrounding TM may be more effective. Preliminary in vitro and in vivo studies using mesenchymal stem cells from TNBC patient’s AT (MSCTNBC) showed how a conditioned medium (CM) prepared from MSCTNBC (MSCTNBC-CM) promoted tumorigenicity, invasion, and chemoresistance. In the present work, molecular mechanism will be investigated to identify novel druggable targets in TNBC.


TNBC cells (MDA-MB-231, BT549, and HS578T) were exposed to MSCTNBC-CM. The activation profile of tyrosine kinase receptors (RTKs) was evaluated using a commercial array. The effect of the inhibitors in the absence and presence of MSCTNBC-CM on TNBC cells recurrence potential, invasion, and cell death were evaluated in vitro through clonogenic, matrix invasion, and flow cytometry assays. Impact on tumour growth was evaluated in a MSCTNBC-TNBC preclinical model (BALB-nu mice).


RTKs activation profile in response to MSCTNBC-CM revealed that TM secreted factors activates Src protein family (SFK) in TNBC. The use of the SFK inhibitor Dasatinib, both in vitro and in vivo, showed a marked reduction of invasion and recurrence potential, an induction of cell death, and a lower of tumour growth.


In this study, we describe SFK as mediators in the communication within the tumour adipose niche and provides fundamental information to understand TNBC progression, as well as its behavior in response to chemotherapy. The specific blockade of the SFK signaling pathway with Dasatinib can interrupt this communication and revert TM protective effect, resulting in death and smaller tumour size. Our results open the gate to the development of new strategies targeting TM to treat TNBC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Diputación de Albacete.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.